AI Article Synopsis
- A study in a malaria-endemic village in southeastern Thailand assessed the effectiveness of circumsporozoite (CS) antibodies as an indicator of malaria transmission through a 25-month monitoring period.
- The levels of CS antibodies increased during peak transmission periods and decreased during non-transmission seasons, aligning with patterns observed in traditional malaria measurement methods.
- Unlike asexual blood stage antibodies, which remained constant, CS antibodies varied with age and were responsive to environmental conditions and mosquito activity, making them a valid marker for understanding malaria transmission dynamics.
Article Abstract
In a longitudinal study of a malaria-endemic village in southeastern Thailand, circumsporozoite (CS) antibody to sporozoites of Plasmodium falciparum was measured by an enzyme-linked immunosorbent assay to determine its usefulness as a seroepidemiologic marker of malaria transmission. The CS anti-(NANP)n antibody level and prevalence during a 25-month period paralleled the pattern of seasonal transmission consistent with conventional parasitologic and entomologic measurements. The prevalence and level of antibody decreased during the non-transmission wet season, and increased over a 1-2-month transition period between the end of monsoon rains and the onset of dry conditions, an interval of maximum vector activity. Antibody increased with age in the population. The prevalence of antibody to the asexual blood stage as measured by conventional indirect fluorescent antibody assay did not coincide with changes in transmission and was sustained throughout the study period. Thus, CS antibody appeared to reflect the relative population exposure to mosquito inoculation of P. falciparum sporozoites and provided a useful measure of malaria transmission dynamics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4269/ajtmh.1992.47.489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein.
Science
January 2025
Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
The most advanced monoclonal antibodies (mAbs) and vaccines against malaria target the central repeat region or closely related sequences within the circumsporozoite protein (PfCSP). Here, using an antigen-agnostic strategy to investigate human antibody responses to whole sporozoites, we identified a class of mAbs that target a cryptic PfCSP epitope that is only exposed after cleavage and subsequent pyroglutamylation (pGlu) of the newly formed N terminus. This pGlu-CSP epitope is not targeted by current anti-PfCSP mAbs and is not included in the licensed malaria vaccines.
View Article and Find Full Text PDFIdentifying Plasmodium P36 and P52 antigens for coadministration with circumsporozoite protein to enhance vaccine efficacy.
NPJ Vaccines
December 2024
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Vaccines targeting the complex pre-erythrocytic stage of Plasmodium parasites may benefit from the inclusion of multiple antigens. However, discerning protective effects can be difficult because newer candidates may not be as protective as leading antigens like the circumsporozoite protein (CSP) in the conventional pre-clinical mouse model. We developed a modified mouse model challenge strategy that maximizes the contribution of T cells induced by novel candidate antigens at the sporozoite challenge time point and used this approach to test Plasmodium P36 and P52 vaccine candidates alone and in concert with non-protective doses of CSP.
View Article and Find Full Text PDFPlacental malaria and circumsporozoite protein-specific immunity.
Trends Parasitol
January 2025
Department of Infectious Diseases, The Peter Doherty Institute of Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia.
Circumsporozoite protein-specific active and passive immunization can protect significantly against Plasmodium falciparum malaria and are being considered as tools to prevent placental malaria. Despite recent encouraging findings, a closer view of the underlying biology indicates significant challenges to preventing placental malaria.
View Article and Find Full Text PDFSafety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite.
N Engl J Med
November 2024
From Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden (O.A.C.L., B.M.D.F-.F., J.P.R.K., G.V.T.R., J.J.J., S.C.C.-M., F.J.A.G., H.M.B.-R., E.I., E.C., E.W., E.L.H., R.M., C.J.J., M.R.), and the Department of Medical Microbiology, Radboud University Medical Center, Nijmegen (G.-J.G., M.V.-B., W.G., T.R.S., B.G.M., T.B., M.B.B.M.) - both in the Netherlands.
Background: Currently licensed and approved malaria subunit vaccines provide modest, short-lived protection against malaria. Immunization with live-attenuated malaria parasites is an alternative vaccination strategy that has potential to improve protection.
Methods: We conducted a double-blind, controlled clinical trial to evaluate the safety, side-effect profile, and efficacy of immunization, by means of mosquito bites, with a second-generation genetically attenuated parasite (GA2) - a single knockout NF54 parasite (sporozoite form) with extended development into the liver stage.
Modular Display of Circumsporozoite Surface Protein and Merozoite Surface Protein-1 on Norovirus-like Particles.
Bioconjug Chem
December 2024
Laboratory of Biotechnology, Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya Suruga-ku, Shizuoka 422-8529, Japan.
Recently, virus-like particles have been regarded as a promising platform for displaying foreign peptides or proteins on their surface. In this study, a dual-protein-displaying platform based on the norovirus-like particle (NoV-LP) was developed using SpyTag (SpT)/SpyCatcher (SpC) protein bioconjugation. A short 14-amino-acid SpT peptide was added to the C-terminus of VP1, with a rigid "EAAAK" spacer in between.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!